2013 consolidated income increases to €30.5 million
11% growth of in vitro diagnostic product sales
PARIS, Jan. 28, 2014 (GLOBE NEWSWIRE) -- Diaxonhit, the leading French provider of specialty diagnostic solutions, announces consolidated income (1) as of December 31, 2013 at €30.5 million, an increase of 8% compared to pro forma income of €28.2 million as of December 31, 2012.
Total sales of in vitro diagnostic products recorded within Diaxonhit's commercial activities, reached €26.3 million, an increase of 11% compared to sales of €23.8 million recorded for the year 2012.
« In 2013, the performance of our sales team is quite remarkable since the year was particularly difficult in France for the in vitro diagnostics industry with total yearly industry sales decreasing by 2.3% at the end of last October. Our focus on specialty diagnostics, and more specifically transplantation, is one the factors that enabled our group to further progress this year. One year after our acquisition of InGen, this success also demonstrates that both companies are well integrated. » said Loïc Maurel, President of Diaxonhit's management board.
Next financial release : Yearly results for 2013, March 26, 2014
Diaxonhit (NYSE Alternext, FR0004054427, ALEHT) is a French fully integrated leader in the in vitro diagnostic field, involved from research to commercialization of specialty diagnostic products.
With many partnerships and a strong presence in hospitals, Diaxonhit has an extensive commercialization network. Through its affiliate, InGen, it commercializes and services, mostly under exclusivity agreements, in vitro diagnostic kits and advanced equipment. It operates mainly in the fields of transplantation, infectious diseases and autoimmunity, product quality control and rapid tests, including Tetanus Quick Stick ®, a proprietary product. InGen is the leading supplier in France of HLA tests manufactured by Thermo-Fisher/One Lambda, of which it is the largest distributor worldwide.
The group also owns a diversified portfolio of products in development, including both innovative molecular and non-molecular diagnostics, covering three main specialty areas: transplantation, immuno-infection and cancer.
Diaxonhit headquarters are located in Paris and its affiliate in the Paris region. The Group is listed on NYSE Alternext in Paris and is part of the NYSE Alternext OSEO innovation index.
For more information, please visit: http://www.diaxonhit.com
This press release contains elements that are not historical facts including, without limitation, certain statements about future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.
In addition, Diaxonhit, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.
Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.
CONTACT: DIAXONHIT Herve Duchesne de Lamotte CFO +33 1 53 94 52 49 email@example.com ACTIFIN Financial Communication + 33 1 56 88 11 11 Investors Relations Alexandre Commerot, firstname.lastname@example.org Press Relations Jennifer Jullia, email@example.comSource:Diaxonhit